Lineage Cell TherapeuticsLCTX
LCTX
About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Employees: 75
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5,700% more call options, than puts
Call options by funds: $58K | Put options by funds: $1K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
1% more funds holding
Funds holding: 113 [Q2] → 114 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
2.66% less ownership
Funds ownership: 53.1% [Q2] → 50.44% (-2.66%) [Q3]
14% less capital invested
Capital invested by funds: $100M [Q2] → $86.2M (-$13.8M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
201%
upside
Avg. target
$4.67
603%
upside
High target
$9
1,257%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Michael Okunewitch 43% 1-year accuracy 3 / 7 met price target | 352%upside $3 | Buy Maintained | 10 Jan 2025 |
D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target | 201%upside $2 | Buy Maintained | 3 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 30% 1-year accuracy 118 / 399 met price target | 1,257%upside $9 | Buy Maintained | 4 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company's recent achievements and outlook for 2025. Dear Fellow Shareholders, We hope you had a restful holiday season and wish you a happy new year. As we look at our plans for the new year, we want to update you on our recent progress and.
Positive
Zacks Investment Research
1 month ago
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineage's common shares.
Negative
Zacks Investment Research
2 months ago
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688.
Neutral
Seeking Alpha
2 months ago
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “We were delighted to see our partners' continued commitment to the OpRegen program, in this inst.
Neutral
Business Wire
2 months ago
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:3.
Neutral
Business Wire
3 months ago
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit, in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research. Lineage's fireside chat will be available for.
Charts implemented using Lightweight Charts™